A citation-based method for searching scientific literature

Akshyaya Pradhan, Monika Bhandari, Pravesh Vishwakarma, Rishi Sethi. Int J Angiol 2020
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An introduction to Markov modelling for economic evaluation.
A Briggs, M Sculpher. Pharmacoeconomics 1998
554
50

The implications of therapeutic complexity on adherence to cardiovascular medications.
Niteesh K Choudhry, Michael A Fischer, Jerry Avorn, Joshua N Liberman, Sebastian Schneeweiss, Juliana Pakes, Troyen A Brennan, William H Shrank. Arch Intern Med 2011
203
50

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
Takeru Shiroiwa, Yoon-Kyoung Sung, Takashi Fukuda, Hui-Chu Lang, Sang-Cheol Bae, Kiichiro Tsutani. Health Econ 2010
438
50

Impact of secondary cardiovascular events on health status.
Henk F van Stel, Jan J V Busschbach, M G Myriam Hunink, Erik Buskens. Value Health 2012
5
50

Dosing frequency and medication adherence in chronic disease.
Craig I Coleman, Brendan Limone, Diana M Sobieraj, Soyon Lee, Matthew S Roberts, Rajbir Kaur, Tawfikul Alam. J Manag Care Pharm 2012
244
50

Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis.
Kunal Srivastava, Anamika Arora, Aditi Kataria, Joseph C Cappelleri, Alesia Sadosky, Andrew M Peterson. Patient Prefer Adherence 2013
108
50

Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
Jens Jakob Thune, James E Signorovitch, Lars Kober, John J V McMurray, Karl Swedberg, Jean Rouleau, Aldo Maggioni, Eric Velazquez, Robert Califf, Marc A Pfeffer,[...]. Eur J Heart Fail 2011
60
50

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
Don Husereau, Michael Drummond, Stavros Petrou, Chris Carswell, David Moher, Dan Greenberg, Federico Augustovski, Andrew H Briggs, Josephine Mauskopf, Elizabeth Loder. Pharmacoeconomics 2013
97
50

Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes.
Prakash C Deedwania, Terje R Pedersen, David A DeMicco, Andrei Breazna, D John Betteridge, Graham A Hitman, Paul Durrington, Andrew Neil. Int J Cardiol 2016
15
50

Discontinuation of statins in routine care settings: a cohort study.
Huabing Zhang, Jorge Plutzky, Stephen Skentzos, Fritha Morrison, Perry Mar, Maria Shubina, Alexander Turchin. Ann Intern Med 2013
388
50

The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Zanfina Ademi, Richard Ofori-Asenso, Ella Zomer, Alice Owen, Danny Liew. Eur J Prev Cardiol 2020
9
50

Economic impact of medication non-adherence by disease groups: a systematic review.
Rachelle Louise Cutler, Fernando Fernandez-Llimos, Michael Frommer, Charlie Benrimoj, Victoria Garcia-Cardenas. BMJ Open 2018
252
50

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Robert Dufour, Mahir Karakas, Tim Hall, Roland P T Troquay, Traci Turner, Frank L J Visseren,[...]. N Engl J Med 2017
447
50

Why clinical trial outcomes fail to translate into benefits for patients.
Carl Heneghan, Ben Goldacre, Kamal R Mahtani. Trials 2017
142
50

Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.
Laura Catherine Edney, Hossein Haji Ali Afzali, Terence Chai Cheng, Jonathan Karnon. Pharmacoeconomics 2018
96
50

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.
Linda J Cobiac, Anne Magnus, Jan J Barendregt, Rob Carter, Theo Vos. BMC Public Health 2012
45
50

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Sabina A Murphy, Terje R Pedersen, Zbigniew A Gaciong, Richard Ceska, Marat V Ezhov, Derek L Connolly, J Wouter Jukema, Kalman Toth, Matti J Tikkanen, Kyungah Im,[...]. JAMA Cardiol 2019
40
50

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
50

Are PCSK9 Inhibitors Cost Effective?
Max J Korman, Kjetil Retterstøl, Ivar Sønbø Kristiansen, Torbjørn Wisløff. Pharmacoeconomics 2018
15
50

Multivariate Meta-Analysis of Preference-Based Quality of Life Values in Coronary Heart Disease.
Jelena Stevanović, Petros Pechlivanoglou, Marthe A Kampinga, Paul F M Krabbe, Maarten J Postma. PLoS One 2016
14
50

Economic evaluation of medicines.
Colman Taylor, Stephen Jan. Aust Prescr 2017
30
50

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
50

An international model to predict recurrent cardiovascular disease.
Peter W F Wilson, Ralph D'Agostino, Deepak L Bhatt, Kim Eagle, Michael J Pencina, Sidney C Smith, Mark J Alberts, Jean Dallongeville, Shinya Goto, Alan T Hirsch,[...]. Am J Med 2012
132
50

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
50

Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, Scott D Solomon, Kevin P Weinfurt, Eric J Velazquez, Robert M Califf, Jean-Lucien Rouleau, Lars Kober, Harvey D White,[...]. JACC Heart Fail 2014
65
50

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
50

Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention.
Matias B Yudi, David J Clark, Omar Farouque, Nick Andrianopoulos, Andrew E Ajani, Angela Brennan, Jeffrey Lefkovits, Melanie Freeman, Chin Hiew, Laura A Selkrig,[...]. Am Heart J 2019
10
50

Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis.
Kanila Perera, Zanfina Ademi, Danny Liew, Ella Zomer. Eur J Prev Cardiol 2019
6
50

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K Ray, R Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A Leiter, Frederick J Raal, Jenna A Bisch, Tara Richardson, Mark Jaros, Peter L J Wijngaard,[...]. N Engl J Med 2020
277
50

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia.
Constantine E Kosmas, Delia Silverio, Julio Ovalle, Peter D Montan, Eliscer Guzman. Patient Prefer Adherence 2018
15
50

The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.
Ella Zomer, Danny Liew, Andrew Tonkin, James M Trauer, Zanfina Ademi. Int J Cardiol 2019
11
50


Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Konstantinos C Koskinas, George C M Siontis, Raffaele Piccolo, Dimitris Mavridis, Lorenz Räber, François Mach, Stephan Windecker. Eur Heart J 2018
84
50


Statin therapy for stroke prevention.
Abdullah Nassief, James D Marsh. Stroke 2008
51
50

Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy.
Peter Lindgren, Thomas Kahan, Neil Poulter, Martin Buxton, Patrick Svarvar, Björn Dahlöf, Bengt Jonsson. Eur J Health Econ 2007
24
50

Conversion of the Seattle Angina Questionnaire into EQ-5D utilities for ischemic heart disease: a systematic review and catalog of the literature.
Harindra C Wijeysundera, Sara Farshchi-Zarabi, William Witteman, Maria C Bennell. Clinicoecon Outcomes Res 2014
7
50

An updated review of lipid-modifying therapy.
Leon A Simons. Med J Aust 2019
7
50

Marine Omega-3 Fatty Acids and Cardiovascular Disease Prevention: Seeking Clearer Water.
Zareen M Farukhi, Samia Mora, JoAnn E Manson. Mayo Clin Proc 2021
5
50

A Revolution in Omega-3 Fatty Acid Research.
Deepak L Bhatt, Matthew J Budoff, R Preston Mason. J Am Coll Cardiol 2020
11
50

A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese: the Suita study.
Tomonori Okamura, Yoshihiro Kokubo, Makoto Watanabe, Aya Higashiyama, Yuu Ono, Kunihiro Nishimura, Akira Okayama, Yoshihiro Miyamoto. Atherosclerosis 2011
27
50



Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
Robert Klempfner, Aharon Erez, Ben-Zekry Sagit, Ilan Goldenberg, Enrique Fisman, Eran Kopel, Nir Shlomo, Ariel Israel, Alexander Tenenbaum. Circ Cardiovasc Qual Outcomes 2016
93
50



Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future.
Yasuhiro Watanabe, Ichiro Tatsuno. Expert Rev Clin Pharmacol 2017
35
50

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
James Backes, Deborah Anzalone, Daniel Hilleman, Julia Catini. Lipids Health Dis 2016
75
50

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
50

Do Omega-3 Fatty Acids Benefit Health?
Gregory Curfman. JAMA 2020
11
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.